INVESTOR RELATIONS UPDATE
BriaCell also reports that the Company attended the BioCentury biotechnology conference, which was held in New York City last week. Surrounding this conference, BriaCell President & CEO Dr. Wagner is making corporate presentations to a variety of institutional investors and analysts. An updated version of the corporate presentation will be posted on the BriaCell corporate website in concert with these meetings.

"I'm thrilled to make the announcement of launching our development of BriaDX™, which marks the culmination of a very active summer ticking off important operational goals in order to strategically prepare for the clinical trial and research program, and I can say that we are more prepared than ever to most rapidly advance both fronts. Therefore, I believe we are now well positioned to allocate more of our resources towards investor relations, and my New York meetings are the beginning of this", commented Dr. Joseph Wagner.

ABOUT BRIACELL
BriaCell is an immuno-oncology biotechnology company, developing a more targeted and less toxic approach to managing cancer. Immunotherapies have come to the forefront of the fight against cancer, because they harness the body's own immune system in recognizing and selectively destroying the cancer cells, sparing normal ones. Immunotherapy approach is more likely to prevent recurrence and is not expected to produce the serious side effects seen with chemotherapy.

The Company has demonstrated unique and unprecedented results, and is intent on building upon these results to further advance BriaVax™ through the FDA Clinical Trials in order to help cancer patients with no other options. The results of two FDA Phase I clinical trials have been encouraging in terms of both safety and efficacy in patients with advanced, stage-IV breast cancer. Most uniquely, BriaCell has achieved these results in patients who had prior failed the available therapies including various kinds of chemotherapy. In some cases, the lifespan was three to five times longer than expected. The results were targeted, with little to no side effects, and were achieved rapidly, with regression occurring within 6 weeks.

BriaCell is also developing a companion diagnostic technology, called BriaDx™. BriaCell believes that an effective companion diagnostic technology could maximize health outcomes and health economics by predicting which patients would most benefit from BriaVax™ treatment.

The Company is planning to advance its cancer immunotherapy technology in an FDA Phase I/II clinical trial with up to 24 breast cancer patients with advanced stages of solid tumors. The FDA-approved protocol has provision to allow testing the vaccine in selected patients with other cancers as well, including prostate, ovarian, pancreas, lung and bladder cancers among others. Although the focus of the Company is currently breast cancer, it recognizes that upon further proof of concept, its technology may be applicable to such other cancers as well. For further information, please refer to Company's website at www.briacell.com or its YouTube channel www.youtube.com/watch?v=el-yFF1uHoQ

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.

Embedded Video Available: https://www.youtube.com/watch?v=el-yFF1uHoQ